447 related articles for article (PubMed ID: 31357472)
1. Asymmetric (ADMA) and Symmetric (SDMA) Dimethylarginines in Chronic Kidney Disease: A Clinical Approach.
Oliva-Damaso E; Oliva-Damaso N; Rodriguez-Esparragon F; Payan J; Baamonde-Laborda E; Gonzalez-Cabrera F; Santana-Estupiñan R; Rodriguez-Perez JC
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357472
[TBL] [Abstract][Full Text] [Related]
2. Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.
Emrich IE; Zawada AM; Martens-Lobenhoffer J; Fliser D; Wagenpfeil S; Heine GH; Bode-Böger SM
Clin Res Cardiol; 2018 Mar; 107(3):201-213. PubMed ID: 29101459
[TBL] [Abstract][Full Text] [Related]
3. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes.
Tsikas D; Bollenbach A; Hanff E; Kayacelebi AA
Cardiovasc Diabetol; 2018 Jan; 17(1):1. PubMed ID: 29301528
[TBL] [Abstract][Full Text] [Related]
4. Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA).
Tain YL; Hsu CN
Toxins (Basel); 2017 Mar; 9(3):. PubMed ID: 28272322
[TBL] [Abstract][Full Text] [Related]
5. Serum Asymmetric and Symmetric Dimethylarginine and Morbidity and Mortality in Hemodialysis Patients.
Shafi T; Hostetter TH; Meyer TW; Hwang S; Hai X; Melamed ML; Banerjee T; Coresh J; Powe NR
Am J Kidney Dis; 2017 Jul; 70(1):48-58. PubMed ID: 28089476
[TBL] [Abstract][Full Text] [Related]
6. The role of asymmetric and symmetric dimethylarginines in renal disease.
Schwedhelm E; Böger RH
Nat Rev Nephrol; 2011 May; 7(5):275-85. PubMed ID: 21445101
[TBL] [Abstract][Full Text] [Related]
7. Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria.
Zobel EH; von Scholten BJ; Reinhard H; Persson F; Teerlink T; Hansen TW; Parving HH; Jacobsen PK; Rossing P
Cardiovasc Diabetol; 2017 Jul; 16(1):88. PubMed ID: 28697799
[TBL] [Abstract][Full Text] [Related]
8. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study.
Aucella F; Maas R; Vigilante M; Tripepi G; Schwedhelm E; Margaglione M; Gesualdo L; Boeger R; Zoccali C
Atherosclerosis; 2009 Dec; 207(2):541-5. PubMed ID: 19501358
[TBL] [Abstract][Full Text] [Related]
9. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
Busch M; Fleck C; Wolf G; Stein G
Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
[TBL] [Abstract][Full Text] [Related]
10. Association of asymmetric dimethylarginine and endothelial dysfunction.
Böger RH
Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
[TBL] [Abstract][Full Text] [Related]
11. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease.
Böger RH; Zoccali C
Atheroscler Suppl; 2003 Dec; 4(4):23-8. PubMed ID: 14664899
[TBL] [Abstract][Full Text] [Related]
12. Association of Uremic Solutes With Cardiovascular Death in Diabetic Kidney Disease.
Sapa H; Gutiérrez OM; Shlipak MG; Katz R; Ix JH; Sarnak MJ; Cushman M; Rhee EP; Kimmel PL; Vasan RS; Schrauben SJ; Feldman HI; Seegmiller JC; Brunengraber H; Hostetter TH; Schelling JR;
Am J Kidney Dis; 2022 Oct; 80(4):502-512.e1. PubMed ID: 35351578
[TBL] [Abstract][Full Text] [Related]
13. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke.
Schulze F; Carter AM; Schwedhelm E; Ajjan R; Maas R; von Holten RA; Atzler D; Grant PJ; Böger RH
Atherosclerosis; 2010 Feb; 208(2):518-23. PubMed ID: 19700158
[TBL] [Abstract][Full Text] [Related]
14. HPLC determination of plasma dimethylarginines: method validation and preliminary clinical application.
Ivanova M; Artusi C; Boffa GM; Zaninotto M; Plebani M
Clin Chim Acta; 2010 Nov; 411(21-22):1632-6. PubMed ID: 20542018
[TBL] [Abstract][Full Text] [Related]
15. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases.
Fleck C; Schweitzer F; Karge E; Busch M; Stein G
Clin Chim Acta; 2003 Oct; 336(1-2):1-12. PubMed ID: 14500028
[TBL] [Abstract][Full Text] [Related]
16. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients.
Fleck C; Janz A; Schweitzer F; Karge E; Schwertfeger M; Stein G
Kidney Int Suppl; 2001 Feb; 78():S14-8. PubMed ID: 11168976
[TBL] [Abstract][Full Text] [Related]
17. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
Betz B; Möller-Ehrlich K; Kress T; Kniepert J; Schwedhelm E; Böger RH; Wanner C; Sauvant C; Schneider R
Transl Res; 2013 Aug; 162(2):67-76. PubMed ID: 23707198
[TBL] [Abstract][Full Text] [Related]
18. Asymmetric dimethylarginine and symmetric dimethylarginine: axis of evil or useful alliance?
Kielstein JT; Fliser D; Veldink H
Semin Dial; 2009; 22(4):346-50. PubMed ID: 19708979
[TBL] [Abstract][Full Text] [Related]
19. Dimethylarginines ADMA and SDMA: the real water-soluble small toxins?
Schepers E; Speer T; Bode-Böger SM; Fliser D; Kielstein JT
Semin Nephrol; 2014 Mar; 34(2):97-105. PubMed ID: 24780466
[TBL] [Abstract][Full Text] [Related]
20. Acetylation of asymmetric and symmetric dimethylarginine: an undercharacterized pathway of metabolism of endogenous methylarginines.
Rodionov RN; Martens-Lobenhoffer J; Brilloff S; Burdin DV; Jarzebska N; Demyanov AV; Hohenstein B; Weiss N; Bode-Böger SM
Nephrol Dial Transplant; 2016 Jan; 31(1):57-63. PubMed ID: 26610597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
